Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma by Mamede, AC et al.
1 23
Pathology & Oncology Research







Oxidative Stress, DNA, Cell Cycle/Cell
Cycle Associated Proteins and Multidrug
Resistance Proteins: Targets of Human





A. M. Abrantes, C. J. Maia, et al.
1 23
Your article is protected by copyright and all
rights are held exclusively by Arányi Lajos
Foundation. This e-offprint is for personal
use only and shall not be self-archived
in electronic repositories. If you wish to
self-archive your article, please use the
accepted manuscript version for posting on
your own website. You may further deposit
the accepted manuscript version in any
repository, provided it is only made publicly
available 12 months after official publication
or later and provided acknowledgement is
given to the original source of publication
and a link is inserted to the published article
on Springer's website. The link must be
accompanied by the following text: "The final
publication is available at link.springer.com”.
ORIGINAL ARTICLE
Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins
and Multidrug Resistance Proteins: Targets of Human Amniotic
Membrane in Hepatocellular Carcinoma
A. C. Mamede1,2,3,4 & S. Guerra1 & M. Laranjo1,3,4 & K. Santos1 & M. J. Carvalho1,3,4,5 &
T. Carvalheiro6 & P. Moura5 & A. Paiva7 & A. M. Abrantes1,3,4 & C. J. Maia2 &
M. F. Botelho1,3,4
Received: 10 January 2016 /Accepted: 7 March 2016
# Arányi Lajos Foundation 2016
Abstract The anticancer effects of human amniotic mem-
brane (hAM) have been studied over the last decade.
However, the action mechanisms responsible for these effects
are not fully understood until now. Previously results reported
by our team proved that hAM is able to induce cytotoxicity
and cell death in hepatocellular carcinoma (HCC), a world-
wide high incident and mortal cancer. Therefore, this experi-
mental study aimed to investigate the cellular targets of hAM
protein extracts (hAMPE) in HCC through in vitro studies.
Our results showed that hAMPE is able to modify oxidative
stress environment in all HCC cell lines, as well as its cell
cycle. hAMPE differently targets deoxyribonucleic acid
(DNA), P21, P53, β-catenin and multidrug resistance
(MDR) proteins in HCC cell lines. In conclusion, hAMPE
has several targets in HCC, being clear that the success of this
treatment depends of a personalized therapy based on the bi-
ological and genetic characteristics of the tumor.
Keywords Human amnioticmembrane . Hepatocellular
carcinoma . Protein extracts . hAMPE .Oxidative stress . Cell
cycle
Introduction
Human amniotic membrane (hAM) is one of the oldest bio-
materials applied in regenerative medicine [1]. In 1910, Davis
reported its application in skin transplantation [2]. Since then,
hAM has been largely applied in several medical procedures
in areas such as ophthalmology or burns treatment [3–6].
Until now, several authors reported successful in vitro and in
vivo results that supported the theory that hAM could also be
applied in cancer therapy. Magatti et al. [7] proved that hAM-
derivedmesenchymal cells (hAMCs) significantly reduced pro-
liferation of hematopoietic and non-hematopoietic cancer cell
lines in cell-cell contact and transwell co-cultures. Cell cycle
arrest at G0/G1 phase was observed, as well as down-regulation
of genes associated with cell cycle progression and up-
regulation of cell cycle negative regulators. Also, Jiao et al.
[8] has found that hAMCs administration suppressed glioma
tumor growth in vivo through the increase of pro-apoptotic
proteins (BAX, caspase-3 and caspase-8) and decrease of
anti-apoptotic proteins (BCL2). hAMCs conditioned medium
also have anti-carcinogenic properties, inhibiting prostate can-
cer cells proliferation and cell cycle [9]. Regarding the anti-
carcinogenic effect of hAM-derived epithelial cells (hAECs),
Kang et al. [10] reported that hAECs were able to inhibit in
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vitro and in vivo breast cancer cells. In addition, a significant
increase in apoptosis rate were observed in cancer cells treated
with hAECs conditioned medium [11].
Recently, Mamede et al. [12] proved that hAM protein
extracts (hAMPE) were able to inhibit some human cancer
cell lines, such as hepatocellular carcinoma (HCC) cell lines
(HuH7, HepG2 and Hep3B2.1–7). After hAMPE treatment,
metabolic activity, protein content and deoxyribonucleic acid
(DNA) content decreased in all HCC cell lines [13]. Through
in vitro and in vivo studies, authors also proved that HCC cell
death profile depends on the cell line signature [13].
Interestingly, hAMPE were not able to inhibit the metabolic
activity, protein content and DNA content of a non-
tumorigenic human cell line (HFF-1) [13].
Given the lack of effective therapies for HCC, it is partic-
ularly important to find new therapies in order to reduce its
mortality [14]. HCC develops in a complex and progressive
process, due to several genetic and epigenetic modifications,
in a rich oxidative stress environment [15, 16]. These modifi-
cations induce autonomous cellular growth and consequent
cell cycle deregulation, as well as several mutations in key
proteins, such as P53, P21 and β-catenin [14, 16–18].
Usually, HCC is diagnosed in advanced stage and patients
can no longer resort to curative therapies, such as transplantation
or partial hepatectomy [19]. Palliative therapies include chemo-
therapy and radiotherapy. However, due to the chemoresistant
and radioresistant HCC profile, these therapies often fail and are
only applied in order to improve the patient’s quality of life [18].
So, taking into account the results already published by our
team [12, 13] and the urgency of new HCC therapies, this
experimental study aimed to find the cellular targets of
hAMPE in HCC through in vitro studies.
Material and Methods
Cell Culture Three human HCC cell lines were considered in
this experimental study: HuH7, HepG2 and Hep3B2.1–7.
HuH7 cells was purchased to Japanese Collection of
Research Bioresources (JCRB, Japan). HepG2 and
Hep3B2.1–7 cells were obtained from American Type
Culture Collection (ATCC, USA). All cell lines were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM - Sigma,
D5648), pH 7.4, supplemented with 10 % fetal bovine serum
(FBS - Sigma, F7524), 1 % antibiotic/antimycotic (Sigma,
A5955) and 0.25 % sodium pyruvate (Gibco, 11,360). Cells
were maintained at 37 °C with 5 % CO2.
hAMPE Preparation hAM were obtained from healthy
women after elective caesarean sections. The study was ac-
complished according to the recommendations of the Ethical
Committee of the Coimbra Hospital and University Centre
(CHUC-70-12, Coimbra, Portugal) after informed consent
provided by women. After reception, hAM samples were
washed with phosphate buffered solution [PBS: 137 mM
NaCl (Sigma, S7653), 2.7 mM KCl (Sigma, P9333), 10 mM
Na2HPO4 (Sigma, S3139), 2 mM KH2PO4 (Sigma, P0662),
pH = 7.4] supplemented with 2 % antibiotic/antimycotic.
hAMPE were prepared as previously described [12]. Briefly,
PBSwas added to the minced hAM samples and then hAMPE
was prepared through a mechanical procedure (homogeniza-
tion, sonication and centrifugation). Supernatants were stored
at −80 °C until protein quantification in NanoDrop (ND-1000
Spectrophotometer, USA). All protocol was performed on ice
without detergents addiction.
Evaluation of Hydrogen Peroxide and Superoxide Radical
Expression To evaluate the hAMPE effect on hydrogen per-
oxide and superoxide radical expression on HCC cell lines,
the probes DCFH-DA and DHE were respectively used.
DCFH-DA is a liposoluble non-fluorescent compound that
is deacetylate by intracellular esterases in the cellular cytosol
and, in the presence of hydrogen peroxide, is oxidized to DCF,
a highly fluorescent compound. Regarding DHE, this com-
pound crosses cell membrane and is converted by the super-
oxide radical to ethidium, a red fluorescent compound that
intercalates into DNA. The quantified fluorescence of DCF
or DHE is respectively proportional to the concentration of
intracellular hydrogen peroxide or superoxide radical [20,
21]. To perform this assay, 1x106 cells were incubated with
1 μg/μL of hAMPE for 72 h. After, cells were incubated with
1 μL of DCFH (5 mM - Sigma, D6883) or 5 μL of DHE
(1 mM – Sigma, 37,291) for 45 min or 15 min, respectively,
at 37 °C in the dark. Cells were then centrifuged (1300×g for
5 min), ressuspended in PBS and DCF fluorescence was de-
termined at 485/20 nm excitation and 528/20 nm emission, as
well as DHE fluorescence was determined at 530/25 nm ex-
citation and 645/40 nm emission [22].
Evaluation of Reduced Glutathione (GSH) Expression In
order to evaluate the GSH expression in HCC cell lines after
hAMPE treatment, we resorted to orange mercury, a fluores-
cent compound that readily reacts with GSH producing an
intense and fluorescent red product [23]. In order to perform
this assay, 1x106 cells were incubated with 1 μg/μL of
hAMPE. After 72 h, cells were incubated with 4 μL of orange
mercury (10 mM - Sigma, M7750) for 15 min at 37 °C in the
dark. Cells were then centrifuged (1300×g for 5 min),
ressuspended in PBS and fluorescence was determined at
485/20 nm excitation and 590/35 nm emission [24].
Evaluation of DNADamage To evaluate if hAMPEmodifies
DNA structural integrity of the HCC cell lines, two techniques
were considered: polyethylene glycol (PEG)/Hoechst frag-
mentation assay and comet assay. To perform both assays,
1x106 cells were incubated with 1 μg/μL of hAMPE for
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72 h. To perform PEG/Hoechst fragmentation assay, lysis
buffer (0.1 % Triton X-100 [Merk Millipore, 108,603],
5 mM Trizma base [Sigma, T1503], pH 8.0, 20 mM EDTA
[Sigma, E6758]) was added, followed by PEG (2.5% - Sigma,
1,546,605) and NaCl (1 M – Sigma, S7653). Cells were
placed on ice for 10 min and centrifuged (16000×g for
10 min). Hoechst 33,258 (0.2 μg/mL in PBS, pH 7.4 –
Sigma, B1155) was added to supernatant (1:1) and, after
20 min of incubation at room temperature, the fluorescence
was determined at 360/40 nm excitation and 460/40 nm emis-
sion [25]. Regarding the comet assay, cells (5x104 cells/mL)
were diluted in low melting point agarose (1 % - Sigma,
A9414) (1:1) and applied in slides (Starfrost), previously over-
laid with normal melting point agarose (1 % - Sigma, A2790).
The slides were submerged in alkaline lysis solution (2.5 M
NaCl, 100 mM EDTA, 10 mM Trizma base, 10 % DMSO
[Sigma, D5879] and 1 % Triton X-100) overnight. After,
slides were equilibrated in alkaline electrophoresis buffer
(300 mM NaOH [Sigma, S5881] and 1 mM EDTA,
pH > 13) and then were submitted to a potential difference
of 254 Vand current of 600 mA for 15 min. After electropho-
resis, slides were incubated in neutralizing buffer (0.4 M
Trizma base, pH = 7.5) for 3 times, 5 min each. Staining with
20 μg/mL of ethidium bromide (BioRad, 161–0433) for
20 min were performed. After, slides were washed in distilled
water and visualized in a fluorescent inverted microscope
Motic with excitation at 540/25 nm and emission at 605/
55 nm. Image acquisition was performed in Motic Images
2.0 (Microscope world, EUA) [26].
Evaluation of Cell Cycle To assess cell cycle in HCC cell
lines after hAMPE treatment, propidium iodide (PI) assay was
used. PI has the ability to intercalate into DNA allowing,
through their quantification, to study the different cell cycle
stages. Once PI also has the ability to intercalate into ribonu-
cleic acid (RNA), RNase must be used. Therefore, to evaluate
if hAMPE treatment induced cell cycle alterations, 1x106 cells
were incubated with 1 μg/μL of hAMPE. After 72 h, cells
were collected, centrifuged (1300×g for 5 min) and fixed un-
der stirring with 200 μL of ice-cold ethanol (70% - Sigma, 24,
102) for 30 min at 4 °C. After centrifugation (1300×g for
5 min), 200 μL of PI/RNase (Immunostep) was added. Cells
were then homogenized and incubated in the dark for 15 min.
After, cells were homogenized and analyzed into a
FACSCalibur cytometer (Becton Dickinson, San José, USA)
with an excitation and emission wavelength of 488 nm and
585/42 nm, respectively. Results were analyzed in the ModFit
LT software (Verity Software House) [26, 27].
Evaluation of P53 and β-Catenin Expression In order to
evaluate the effect of hAMPE in P53 and β-catenin expres-
sion, 1x106 cells were incubated with 1 μg/μL of hAMPE for
72 h. To prepare total protein extracts, cells were incubated on
ice with radioimmunoprecipitation (RIPA) buffer supplement-
ed with Complete Mini (Roche, 11,836,153,001), PhosSTOP
(Roche,04,906,845,001) and 1 mM dithiothreitol (DTT -
Sigma, 43,815), sonicated and centrifuged (14000×g for
15 min). Protein samples were then reserved at −80 °C until
use. Bicinchoninic (BCA) assay (Pierce BCA protein assay
kit) was used to determine protein concentration. After sample
denaturation, electrophoresis was performed with an acrylam-
ide gel. Proteins were then electrotransfered to methanol acti-
vated polyvinylidene fluoride (PVDF) membranes (Merck
Millipore) (100 V). PVDF membranes blocking was per-
formed with 4 % bovine serum albumin (BSA – Sigma
A7906) in tris-buffered saline tween-20 (TBS-T) under stir-
ring for 1 h at room temperature. Incubation with primary
antibodies, P53 (1:200 - Santa Cruz Biotechnology, sc-47,
698), β-catenin (1:200 - Santa Cruz Biotechnology, sc-7963)
and β-actin (1:5000 – Sigma, A5441) was performed over-
night at 4 °C. After TBS-T several washes, membranes were
incubated with anti-mouse secondary antibody (1:3000 - GE
Healthcare) for 1 h at room temperature. After new washes,
blots were stained with fluorescent reagent elemental chlorine
free (ECF - Amersham Biosciences) for 5 min and revealed in
a fluorescence reader (Typhoon FLA 9000). Quantification of
fluorescence was performed using ImageQuant 5.0
(Molecular Dynamics) [26]. Hep3B2.1–7 cell line has a null
P53, as already proved by our team, reason why we not pro-
vided P53 results for this cell line [28, 29].
Evaluation of P-Glycoprotein (PGP), Multidrug
Resistance Protein 1 (MRP1), Lung Resistance Protein
(LRP) and P21 Expression In order to evaluate if hAMPE
induced PGP, MRP1, LRP and P21 expression alteration,
1x106 cells were incubated with 1 μg/μL of hAMPE for
72 h. To evaluate PGP and MRP1 expression, cells were col-
lected, centrifuged (1300×g for 5 min) and incubated with
3 μL of PGP-fluorescein isothiocyanate (FITC - BD
Pharmingen, 557,002) or 3 μL of MRP1-FITC (BD
Pharmingen, 557,593) for 15 min in dark. After, cells were
centrifuged (1300×g for 5 min) and ressuspended in PBS.
Fluorescence was determined at 485/20 nm emission and
528/20 nm emission. In order to evaluate LRP and P21 ex-
pression, cells were collected, centrifuged (1300×g for 5 min)
and incubated with 100 μL of fix solution (IntraCell,
Immunostep) for 15 min. After centrifugation (1300×g for
5 min), cells were then incubated for 15 min with 100 μL of
permeabilization solution (IntraCell, Immunostep) and LRP
(1:50 - Santa Cruz Biotechnology, sc-23,916) or P21 (1:50 -
Santa Cruz Biotechnology, sc-6246). After centrifugation
(1300 g for 5 min), cells were then incubated with anti-
mouse-PE secondary antibody (1:100 - Santa Cruz
Biotechnology, sc-3738) for 20 min in dark. Cells were then
centrifuged (1300×g for 5 min), ressuspended in PBS and
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fluorescence was determined at 485/20 nm emission and 590/
35 nm emission [30, 31].
Statistical Analysis
Statistical analysis was performed in IBM® SPSS® software
v.22.0 (IBM Corporation, Armonk, New York, USA). The
normality distribution of the variables and the homogeneity
of variances were performed according to the Shapiro-Wilk
and Levene tests, respectively. For comet assay, the normality
distribution of the variables were determined through
Kolmogorov-Smirnov test. Parametric Student t-test was used
if a normal distribution and homogeneity of variances were
observed. Otherwise, Mann-Whitney nonparametric test was
considered. If a normal distribution and homogeneous vari-
ances were present, and in order to compare different cell
lines, one-factor analysis of variance (ANOVA) parametric
test was used. Otherwise Kruskal-Wallis nonparametric test
was used. Multiple comparisons were obtained through
Tukey (equal variances assumed) or Games-Howell (no equal
variances assumed) corrections. A significant level of 5 %was
adopted for all comparisons.
Results
hAMPE Modified the Oxidative Stress Environment
in HCC Cell Lines
hAMPE induced an increase of 39 % (p < 0.05) in hydrogen
peroxide levels in HuH7 cell line relatively to control, as can
be seen in Fig. 1a. On the other hand, hAMPE decreased the
levels of this compound by 52 % and 39 % in HepG2 and
Hep3B2.1–7 cells, respectively (p < 0.05). Regarding the su-
peroxide radical (Fig. 1a), hAMPE decreased 42 % (p < 0.05)
its expression in HuH7 cell line. Contrarily, the same treat-
ment induced a superoxide radical increase of 288 %
(p < 0.01) and 37 % (p < 0.05) in HepG2 and Hep3B2.1–7
cell lines, respectively. hAMPE significantly decreased the
expression of GSH in all HCC cell lines when compared to
control cells (Fig. 1b).
hAMPE Targeted DNA in HepG2 Cell Line
Through Fig. 2a, it can be seen that hAMPE induced in in-
crease of 32 % (p < 0.05) in DNA fragmentation in HepG2
cell line. This cell line also presented an increase of 13 times
(p < 0.001) in the tail moment after hAMPE treatment, rela-
tively to control condition (Fig. 2b and 2c). No changes were
detected in DNA fragmentation or tail moment on HuH7 and
Hep3B2.1–7 cell lines.
hAMPE Modified Cell Cycle Profile in HCC Cell Lines
hAMPE treatment decreased the percentage of HuH7 cells in
G0/G1 phase (p < 0.05) and increased the number of cells in
G2/M phase (p < 0.05), as represented in Fig. 3a.
Through Fig. 3b, it can be seen that the percentage of
cells in S phase decreased 17 % (p < 0.05) and in G2/
M phase increased 12 % (p < 0.05) relatively to control
condition in the HepG2 cell line. On the other hand,
hAMPE treatment decreased 48 % of cells in G0/G1
(p < 0.01) phase in Hep3B2.1–7 cell line, as well as increased
5 % of cells in S phase (p < 0.01) (Fig. 3c).
hAMPE Regulated P21, P53 and β-Catenin Expression
in HCC Cell Lines
The P21 expression increased 17 % (p < 0.05) after hAMPE
treatment in HuH7 cell line, as disclosed in Fig. 4a. In contrast,
these treatment induced a decreased of 11 % (p < 0.05) in P21
expression in HepG2 cell line and it was not able to change
P21 expression in Hep3B2.1–7 cells. P53 expression was
inhibited by hAMPE in HuH7 and HepG2 cell lines, as can
be seen in Fig. 4b (p < 0.01). hAMPE was also able to inhibit
β-catenin in all HCC cell lines (p < 0.01), when compared to
control condition (Fig. 4c).
hAMPE Regulated the Expression of Multidrug
Resistance Proteins (MDR) in HCC Cell Lines
After hAMPE treatment, PGP expression decreased 42 %
(p < 0.01) in Hep3B2.1–7 cell line (Fig. 5a). Regarding
MRP1, its expression was 5 % reduced by hAMPE in
HepG2 cell line (p < 0.05), as can be seen in Fig. 5b.
Regarding the LRP multidrug resistance protein, its expres-
sion is not affected by hAMPE in any of the HCC cell lines
under study (Fig. 5c).
Discussion
The interest in hAM anticancer potential has been grow-
ing in the last decade. However, despite the published
results so far, the action mechanisms by which hAM
exerts its effects on the tumor cells are not yet fully
understood [7–10].
In order to discover some of the hAMPE molecular targets,
and taking into account the previously published results [12,
13], we proposed to evaluate in vitro the effect of this therapy
on several cellular molecules and its mechanisms on three
human HCC cell lines.
Through the obtained results, it can be concluded that
hAMPE modified the HCC oxidative stress environment.
The increase of superoxide radical in HepG2 and
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Hep3B2.1–7 cells is probably a result of the high mitochon-
drial membrane potential (MMP) induced by hAMPE treat-
ment, which is in accordance to previously demonstrated [13,
32]. On the other hand, a decrease in superoxide radical was
observed in HuH7 cell line, which can be probably explained
by a fast dismutation of this reactive oxygen species (ROS) by
the superoxide dismutase (SOD) to hydrogen peroxide, whose
levels in these cell line increased after hAMPE treatment [33].
The decrease of hydrogen peroxide in HepG2 and Hep3B2.1–7
cell lines can be probably promoted by a fast conversion of these
ROS in other species more harmful to the cell, such as the
hydroxyl radical, by the Fenton/Habber Weiss reaction [33, 34].
Hydrogen peroxide is efficiently scavenged by the enzyme
glutathione peroxidase (GPx), which requires GSH as electron
donor [33]. Since the levels of hydrogen peroxide decreased
after hAMPE treatment in HepG2 and Hep3B2.1-7 cell lines,
cellular GSH production also decreased since was no longer
necessary for cell detoxification. Previous published results by
our team suggested that intracellular NADPH was compro-
mised after hAMPE treatment, since the metabolic activity
(evaluated through the MTT reaction with NADPH) was
inhibited [13]. Taking into account that oxidised glutathione
(GSSG) is reduced back to GSH by the enzyme glutathione
reductase, which uses NADPH as electron donor, the GSH
Fig. 1 a Hydrogen peroxide, superoxide radical and b GSH expression
in HuH7, HepG2 and Hep3B2.1–7 cell lines after 72 h of incubation with
1 μg/μL of hAMPE. All results are normalized relatively to control
condition (no hAMPE treatment), which was considered equal to 1. For
each condition, results were obtained with a minimum of three hAM.
Graphs represent mean ± standard error. Significant differences are
indicated by *, where * represents p < 0.05, ** represents p < 0.01 and
*** represents p < 0.001
Fig. 2 DNA integrity accessed by (a) PEG-Hoechst fragmentation assay
and (b/c) comet assay in HuH7, HepG2 and Hep3B2.1–7 cell lines after
72 h of incubation with 1 μg/μL of hAMPE. In (A) all results are
normalized relatively to control condition (no hAMPE treatment),
which was considered equal to 1. (b) Tail moment = tail length x
fraction of total DNA in the tail. The data are based on a minimum of
100 comets per condition. For each condition presented in (a) and (b),
results were obtained with a minimum of three hAM. Graphs represent
mean ± standard error. Significant differences are indicated by *, where *
represents p < 0.05 and *** represents p < 0.001. (c) Representative
images of the comet assay for each condition: negative control
(untreated cells – 100×), positive control [cells treated with 20 nM of
hydroxide peroxide (Panreac, 121,076) for 15 min at 4 °C – 100×] and
hAMPE treated cells (100×)
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decrease in all HCC cell lines can be also a consequence of
cellular NADPH commitment [33].
PEG-Hoechst assay allows to quantify small-size (0–1 kb)
fragmented DNA [35]. These fragments are indicators of ne-
crotic and apoptotic DNA damage [35]. So, in accordance
with the results obtained, hAMPE induced an increase of
DNA fragmentation in HepG2 cells, which can corroborate
the apoptotic and necrotic cell death profile induced by
hAMPE in these cell lines [13]. In order to support these
results, comet assay, which allows to detect single and double
strand breaks, was used to evaluate the effect of hAMPE [26].
These results also corroborated the effect triggered by hAMPE
in DNA damage, being this significantly increased in HepG2
cells. The highest levels of superoxide radical in HepG2 cell
line after hAMPE treatment could probably trigger DNA dam-
age and consequent apoptosis and necrosis [36]. Supporting
this effect is the fact that no DNA damage were observed in
HuH7 and Hep3B2.1–7 cell lines, which presents low levels of
superoxide radical when compared to HepG2 cells. However,
we cannot exclude the possibility of intrastranded or
interstranded crosslinking formation [26]. Since we previously
found that hAMPE induced apoptosis in these cell lines, we can
conclude that HuH7 and Hep3B2.1–7 cells may undergo apo-
ptosis without DNA fragmentation [13]. Although is not a com-
mon profile, there are several studies published about early
apoptosis without DNA fragmentation induction [37, 38].
P21 expression is commonly up-regulated by the P53 tu-
mor suppressor gene [39]. However, P21 expression can also
be P53-independently regulated [39]. Since hAMPE de-
creased P53 expression in HuH7 cell line, P21 increase in this
cell line was probably induced by an independent P53 mech-
anism. On the other hand, in wild-type P53 HepG2 cell line,
P21 decreased was probably a direct consequence of P53 in-
hibition by hAMPE treatment. P53 inhibition could be
a consequence of the high DNA damage induced by
hAMPE in HepG2 cell line, since P53 is one of the main
responsible for DNA repair mechanisms [40].
It is well known that P21 might inhibit cell cycle pro-
gression by two independent mechanisms: inhibition of
cyclin/cyclin-dependent kinase (CDK) complexes and in-
hibition of proliferating cell nuclear antigen (PCNA) func-
tion, which results in both G1 and G2 arrest [41]. Since
Fig. 3 Cell cycle analysis of HuH7 (a), HepG2 (b) and Hep3B2.1–7 (c)
cell lines after 72 h of incubation with 1 μg/μL of hAMPE. Results
represent the percentage of cells in the different cell cycle phases: G0/
G1, S and G2/M. For each condition, results were obtained with a
minimum of three hAM. Graphs represent mean ± standard error.
Significant differences are indicated by *, where * represents p < 0.05
and ** represents p < 0.01
Fig. 4 Expression of P21 (a), P53 (b) andβ-catenin (c) in HuH7, HepG2
and Hep3B2.1–7 cells after incubation with 1 μg/μL f hAMPE for 72 h.
All results are normalized relatively to control condition (no hAMPE
treatment) which was considered equal to 1. Results presented in B and
C are presented as the fluorescence intensities ratio between the protein of
interest andβ-actin and are representative of P53 orβ-catenin andβ-actin
expression for each experimental condition. For each condition, results
were obtained with a minimum of three hAM. Graphs represent
mean ± standard error. Significant differences are indicated by *, where
* represents p < 0.05 and ** represents p < 0.01
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hAMPE induced G2/M phase arrest in HuH7 cell lines, it
was likely that increased P21 inhibited PCNA. Since
PCNA acts as a scaffold protein that organizes several
components for DNA replication or cell cycle progression,
PCNA inhibition could probably be responsible for several
experimental results presented by our team in this and oth-
er papers [13, 42]. On the other hand, since hAMPE in-
duced a high DNA damage in HepG2 cell line, and since
G2/M checkpoint is essential for maintaining genome sta-
bility, the HepG2 cell cycle arrest in this phase could be
easily explained [43]. Wu et al. [44] revealed that Wnt
pathway inhibition induced a cell cycle arrest at G2/M
and S phase in HuH7 and Hep3B2.1–7 cell lines, respec-
tively. Considering the similarity with our results, we
should conduct further studies in the future to analyse if
hAMPE is able to inhibit the Wnt pathway in HCC cell
lines. Taking into account our results previously published
[13], the reduction of P53 and β-catenin in all HCC cell
lines can explain the decreased metabolic activity, protein
content, DNA content and cell death induced by hAMPE
treatment [44].
Low response rates to chemotherapy in HCC can partly be
attributed to the expression of MDR proteins [30]. In order to
overcome this problem, pharmacologic inhibition of MDR
transporters has been largely studied, since pharmacological
inhibitors application is based on 1) modulation of MDR pro-
tein activity by competitive inhibition or 2) induction of con-
formational changes in MDR proteins, thus preventing sub-
strate recognition or ATP hydrolysis [31]. In accordance with
our results, we can conclude that hAMPE is able to inhibit
PGP expression in Hep3B2.1–7 cells andMRP1 expression in
HepG2 cells.
On the other hand, hAMPE induced an increase of
MRP1 protein expression in HuH7 cell line. This results
could explain the higher efficacy of hAMPE therapy in
HepG2 and Hep3B2.1–7 cell lines than in HuH7 cell line,
as clearly demonstrated through in vitro and in vivo stud-
ies previously published [13]. It is actually known that the
expression of certain P53 mutants in HCC may enhance
drug resistance [45, 46]. Since HuH7 cell line expresses a
mutated P53, this protein could be responsible for the
drug resistance. Through our results it seems that LRP is
not a target of hAMPE in any of the HCC cell lines under
study.
In conclusion, it seems that hAMPE is able to modify
the oxidative stress environment in all HCC cell lines, as
well as their cell cycle. This treatment also differently
targets DNA, P21, P53, β-catenin and MDR proteins in
HCC cell lines. However, through this experimental
study, it becomes clear that hAMPE treatment output
depends on the biological and genetic characteristic of
each cell line.
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